Insomnia is a prevalent sleep disorder characterized by daytime dysfunction as a result of one or more sleep problems. The treatment of insomnia is highly individualized, and physicians consider multiple factors when selecting an appropriate therapeutic. The primary goal of treatment is to improve patients’ quality of sleep, with minimal next-day side effects. Although generics are entrenched in the insomnia treatment algorithm, new therapies have launched in the U.S. market, such as the dual orexin receptor antagonists Belsomra (Merck) and Dayvigo (Eisai), and the pipeline is becoming increasingly active.
Geographies: United States.
Real-world data: Longitudinal patient-level claims data analysis.
Key drugs covered: Belsomra, Dayvigo, zolpidem IR, zolpidem CR, eszopiclone, trazodone, Rozerem, ramelteon, zaleplon, doxepin, BZDs.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.